A cholestanoid consisting of cholestane having a double bond at the 5,6-position as well as a 3beta-hydroxy group.
Chemical ID:
MESH:D002784
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the abundance of Reactive Oxygen Species; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the expression of SOD2 mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased activity of CAT protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of CAT mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of MKI67 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of TP53 mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP3 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP9 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the abundance of Reactive Oxygen Species; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the abundance of Reactive Oxygen Species]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of CAT mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of MKI67 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of SOD2 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of TP53 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased activity of CAT protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased expression of MKI67 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] inhibits the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in decreased activity of CASP3 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of MKI67 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of TP53 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased susceptibility to Silver Compounds; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in decreased expression of MKI67 protein]; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in increased activity of CAT protein]; EGF protein affects the susceptibility to [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds]; EGF protein inhibits the reaction [[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the abundance of Reactive Oxygen Species]
